Dr. Reddy's Laboratories Limited — Board Meeting, 23-07-2025: Outcome of Board Meeting

Dr. Reddy's board greenlit the quarter's financial results. Consolidated revenue hit ₹8,545.2 Cr, up 11% YoY, flat QoQ. Profit after tax grew 2% YoY to ₹1,417.8 Cr, though down 11% QoQ. EBITDA rose 5% YoY to ₹2,278.4 Cr. North America generics revenue saw an 11% YoY dip due to price erosion, notably Lenalidomide. Europe's strong growth was fueled by the acquired NRT business. Key strategic updates include new partnerships for a Keytruda biosimilar and an RSV drug in India, and an allergy product launch. USFDA inspections flagged VAI observations at two API sites.